Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prophylactic Antibiotics in Admitted Cirrhotics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04218695
Recruitment Status : Recruiting
First Posted : January 6, 2020
Last Update Posted : July 20, 2021
Sponsor:
Collaborator:
American Association for the Study of Liver Diseases Foundation
Information provided by (Responsible Party):
Zachary Fricker, Beth Israel Deaconess Medical Center

Brief Summary:
In this pilot study, the investigators aim to assess feasibility of subject identification and data collection, including specimen processing, as well as the rate of enrollment for a future, larger study of the effect of empiric antibiotics for all patients with advanced cirrhosis admitted to the hospital without an existing indication for new antibiotic use. Specifically, the investigators will assess the incidence of infection after the time of enrollment and associated outcomes. Subjects will be randomly assigned to receive antibiotics vs placebo.

Condition or disease Intervention/treatment Phase
Cirrhosis, Liver Drug: Ceftriaxone Drug: Normal saline Phase 4

Detailed Description:
Cirrhosis is associated with a state of immune-compromise and progressive decompensation, acute on chronic liver failure (ACLF), and death are often caused by bacterial infections. Different sub-groups of patients with cirrhosis at increased risk, i.e. active upper gastrointestinal hemorrhage, low protein ascites, history of spontaneous bacterial peritonitis (SBP), are known to benefit from prophylactic antibiotics. The investigators hypothesize that hospitalized patients with advanced cirrhosis are also at increased risk and thus may benefit from preventive treatment. Subjects will be randomly assigned to receive an antibiotic vs placebo.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double-blinded placebo-controlled trial
Primary Purpose: Prevention
Official Title: A Pilot Study of the Effect of Prophylactic Antibiotics on Hospitalized Patients With Advanced Cirrhosis
Actual Study Start Date : August 24, 2020
Estimated Primary Completion Date : December 30, 2021
Estimated Study Completion Date : June 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antibiotics

Arm Intervention/treatment
Experimental: Treatment
1 gram intravenous ceftriaxone once daily for up to one week or until end of hospitalization
Drug: Ceftriaxone
Antibiotic
Other Name: Rocephin

Placebo Comparator: Placebo
Normal saline (50cc) once daily for up to one week or until end of hospitalization
Drug: Normal saline
50cc intravenous once daily
Other Name: Placebo




Primary Outcome Measures :
  1. Infections [ Time Frame: For 7 days or until end of hospital stay ]
    Incident bacterial infection after enrollment


Secondary Outcome Measures :
  1. Length of stay [ Time Frame: Up to 30 days ]
    Days in hospital after randomization

  2. Mortality [ Time Frame: Up to 30 days ]
    In-hospital

  3. 30-day mortality [ Time Frame: Up to 30-days ]
    Includes f/u after discharge


Other Outcome Measures:
  1. Incident C difficile colitis [ Time Frame: 30 days ]
    Positive stool toxin/PCR with new onset diarrhea

  2. Incident ACLF [ Time Frame: During hospital admission up to 30 days ]
    (by NACSELD) or change in CLIF-C ACLF score

  3. Incident variceal hemorrhage [ Time Frame: During hospital admission up to 30 days ]
    Incident variceal hemorrhage

  4. Increase in MELD-Na [ Time Frame: Upon discharge (or at 30 days) ]
    >2 pts

  5. Fungal infection [ Time Frame: During hospital admission up to 30 days ]
    Incident fungal infection (by culture data or requirement for new anti-fungal medication)

  6. Biomarkers of infection [ Time Frame: Once at time of randomization ]
    Procalcitonin and C-reactive protein



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • MELD-Na >= 18
  • Cirrhosis as defined by liver biopsy or a composite assessment of available results from imaging, elastography, prior records, and laboratory studies

Exclusion Criteria:

  • Inability to obtain consent (from subject or next of kin/legal authorized representative (LAR)
  • Allergy to cephalosporins
  • Pregnancy (due to limited prospective data regarding safety of ceftriaxone)
  • Existing indication for new antibiotics, e.g. upper gastrointestinal hemorrhage or apparent infection
  • Use of major immunosuppressive medications (e.g. prednisone 20 mg/day or greater, immunosuppression for solid organ transplant)
  • H/o recurrent C difficile infection within the past year (>2) or requiring fecal microbiota transplant (FMT)
  • Enrollment in the study protocol during a previous admission

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04218695


Locations
Layout table for location information
United States, Massachusetts
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Zachary Fricker, MD    617-632-1070    research@bidmc.harvard.edu   
Sponsors and Collaborators
Beth Israel Deaconess Medical Center
American Association for the Study of Liver Diseases Foundation
Investigators
Layout table for investigator information
Principal Investigator: Zachary P Fricker, MD Beth Israel Deaconess Medical Center
Layout table for additonal information
Responsible Party: Zachary Fricker, Instructor, Division of Gastroenterology, Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier: NCT04218695    
Other Study ID Numbers: 2020P000050
BIDMC-ABX-pilot-19 ( Other Identifier: Beth Israel Deaconess Medical Center )
First Posted: January 6, 2020    Key Record Dates
Last Update Posted: July 20, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Cirrhosis
Fibrosis
Pathologic Processes
Liver Diseases
Digestive System Diseases
Ceftriaxone
Anti-Bacterial Agents
Anti-Infective Agents